Sec Form 13G Filing - YA II PN, Ltd. filing for - 2026-04-20

Insider filing report for Changes in Beneficial Ownership

  • Schedule 13G & 13D forms are used to report a party's ownership of stock which exceeds 5% of a company's total stock issue.
  • Schedule 13G is a shorter version of Schedule 13D with fewer reporting requirements.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>





Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
Checkbox not checked   Rule 13d-1(b)
Checkbox checked   Rule 13d-1(c)
Checkbox not checked   Rule 13d-1(d)




schemaVersion:


SCHEDULE 13G



Comment for Type of Reporting Person:  Pursuant to the Standby Equity Purchase Agreement entered into on April 6, 2026 (the "Purchase Agreement") between YA II PN, Ltd. ("YA II") and TransCode Therapeutics, Inc. (the "Issuer"), YA II purchased a convertible promissory note on April 15, 2026 (the "Convertible Note") which may be converted by YA II, from time to time, into shares of Common Stock, par value $0.0001 per share ("Common Stock"), and may acquire additional shares of Common Stock in accordance with the Purchase Agreement. YA II is prohibited from acquiring any shares of Common Stock pursuant to the Purchase Agreement or the Convertible Note which when aggregated with all other shares of Common Stock then owned by YA II and its affiliates, would result in the beneficial ownership by YA II and its affiliates to exceed 9.99% of the Common Stock outstanding. Calculation based on 1,018,740 shares of Common Stock, consisting of 916,968 shares of Common Stock outstanding as of April 3, 2026, plus an additional 101,772 shares of Common Stock that YA II may receive upon conversion of the Convertible Note.


SCHEDULE 13G



Comment for Type of Reporting Person:  Pursuant to the Purchase Agreement, YA II purchased Convertible Note which may be converted by YA II, from time to time, into shares of Common Stock and may acquire additional shares of Common Stock in accordance with the Purchase Agreement. YA II is prohibited from acquiring any share of Common Stock pursuant to the Purchase Agreement or the Convertible Note which when aggregated with all other shares of Common Stock then owned by YA II and its affiliates, would result in the beneficial ownership by YA II and its affiliates to exceed 9.99% of the Common Stock outstanding. Calculation based on 1,018,740 shares of Common Stock, consisting of 916,968 shares of Common Stock outstanding as of April 3, 2026, plus an additional 101,772 shares of Common Stock that YA II may receive upon conversion of the Convertible Note.


SCHEDULE 13G



Comment for Type of Reporting Person:  Pursuant to the Purchase Agreement, YA II purchased Convertible Note which may be converted by YA II, from time to time, into shares of Common Stock and may acquire additional shares of Common Stock in accordance with the Purchase Agreement. YA II is prohibited from acquiring any share of Common Stock pursuant to the Purchase Agreement or the Convertible Note which when aggregated with all other shares of Common Stock then owned by YA II and its affiliates, would result in the beneficial ownership by YA II and its affiliates to exceed 9.99% of the Common Stock outstanding. Calculation based on 1,018,740 shares of Common Stock, consisting of 916,968 shares of Common Stock outstanding as of April 3, 2026, plus an additional 101,772 shares of Common Stock that YA II may receive upon conversion of the Convertible Note.


SCHEDULE 13G



Comment for Type of Reporting Person:  Pursuant to the Purchase Agreement, YA II purchased Convertible Note which may be converted by YA II, from time to time, into shares of Common Stock and may acquire additional shares of Common Stock in accordance with the Purchase Agreement. YA II is prohibited from acquiring any share of Common Stock pursuant to the Purchase Agreement or the Convertible Note which when aggregated with all other shares of Common Stock then owned by YA II and its affiliates, would result in the beneficial ownership by YA II and its affiliates to exceed 9.99% of the Common Stock outstanding. Calculation based on 1,018,740 shares of Common Stock, consisting of 916,968 shares of Common Stock outstanding as of April 3, 2026, plus an additional 101,772 shares of Common Stock that YA II may receive upon conversion of the Convertible Note.


SCHEDULE 13G



Comment for Type of Reporting Person:  Pursuant to the Purchase Agreement, YA II purchased Convertible Note which may be converted by YA II, from time to time, into shares of Common Stock and may acquire additional shares of Common Stock in accordance with the Purchase Agreement. YA II is prohibited from acquiring any share of Common Stock pursuant to the Purchase Agreement or the Convertible Note which when aggregated with all other shares of Common Stock then owned by YA II and its affiliates, would result in the beneficial ownership by YA II and its affiliates to exceed 9.99% of the Common Stock outstanding. Calculation based on 1,018,740 shares of Common Stock, consisting of 916,968 shares of Common Stock outstanding as of April 3, 2026, plus an additional 101,772 shares of Common Stock that YA II may receive upon conversion of the Convertible Note.


SCHEDULE 13G



Comment for Type of Reporting Person:  Pursuant to the Purchase Agreement, YA II purchased Convertible Note which may be converted by YA II, from time to time, into shares of Common Stock and may acquire additional shares of Common Stock in accordance with the Purchase Agreement. YA II is prohibited from acquiring any share of Common Stock pursuant to the Purchase Agreement or the Convertible Note which when aggregated with all other shares of Common Stock then owned by YA II and its affiliates, would result in the beneficial ownership by YA II and its affiliates to exceed 9.99% of the Common Stock outstanding. Calculation based on 1,018,740 shares of Common Stock, consisting of 916,968 shares of Common Stock outstanding as of April 3, 2026, plus an additional 101,772 shares of Common Stock that YA II may receive upon conversion of the Convertible Note.


SCHEDULE 13G



Comment for Type of Reporting Person:  Pursuant to the Purchase Agreement, YA II purchased Convertible Note which may be converted by YA II, from time to time, into shares of Common Stock and may acquire additional shares of Common Stock in accordance with the Purchase Agreement. YA II is prohibited from acquiring any share of Common Stock pursuant to the Purchase Agreement or the Convertible Note which when aggregated with all other shares of Common Stock then owned by YA II and its affiliates, would result in the beneficial ownership by YA II and its affiliates to exceed 9.99% of the Common Stock outstanding. Calculation based on 1,018,740 shares of Common Stock, consisting of 916,968 shares of Common Stock outstanding as of April 3, 2026, plus an additional 101,772 shares of Common Stock that YA II may receive upon conversion of the Convertible Note.


SCHEDULE 13G



Comment for Type of Reporting Person:  Pursuant to the Purchase Agreement, YA II purchased Convertible Note which may be converted by YA II, from time to time, into shares of Common Stock and may acquire additional shares of Common Stock in accordance with the Purchase Agreement. YA II is prohibited from acquiring any share of Common Stock pursuant to the Purchase Agreement or the Convertible Note which when aggregated with all other shares of Common Stock then owned by YA II and its affiliates, would result in the beneficial ownership by YA II and its affiliates to exceed 9.99% of the Common Stock outstanding. Calculation based on 1,018,740 shares of Common Stock, consisting of 916,968 shares of Common Stock outstanding as of April 3, 2026, plus an additional 101,772 shares of Common Stock that YA II may receive upon conversion of the Convertible Note.


SCHEDULE 13G


 
YA II PN, Ltd.
 
Signature:/s/ David Gonzalez
Name/Title:David Gonzalez, General Counsel
Date:04/20/2026
 
YA Global Investments II (U.S.), LP
 
Signature:/s/ David Gonzalez
Name/Title:David Gonzalez, General Counsel
Date:04/20/2026
 
Yorkville Advisors Global, LP
 
Signature:/s/ David Gonzalez
Name/Title:David Gonzalez, General Counsel
Date:04/20/2026
 
Yorkville Advisors Global II, LLC
 
Signature:/s/ David Gonzalez
Name/Title:David Gonzalez, General Counsel
Date:04/20/2026
 
YAII GP, LP
 
Signature:/s/ David Gonzalez
Name/Title:David Gonzalez, General Counsel
Date:04/20/2026
 
YAII GP II, LLC
 
Signature:/s/ David Gonzalez
Name/Title:David Gonzalez, General Counsel
Date:04/20/2026
 
Mark Angelo
 
Signature:/s/ Mark Angelo
Name/Title:Mark Angelo
Date:04/20/2026
 
SC-Sigma Global Partners, LP
 
Signature:/s/ David Gonzalez
Name/Title:David Gonzalez, General Counsel
Date:04/20/2026
primary_doc.xml